Key Developments: Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

199.80USD
4:00pm EDT
Price Change (% chg)

$0.38 (+0.19%)
Prev Close
$199.42
Open
$201.16
Day's High
$201.56
Day's Low
$198.77
Volume
295,971
Avg. Vol
407,366
52-wk High
$264.94
52-wk Low
$129.61

Search Stocks

Latest Key Developments (Source: Significant Developments)

Shire Plc raises FY 2014 EPS guidance
Friday, 24 Oct 2014 07:05am EDT 

Shire Plc:Expects to deliver non GAAP earnings per ADS growth in high thirty percent range in FY 2014 (previous guidance: low-to-mid thirty percent growth).Reported EPS of $7.36 in FY 2013.FY 2014 EPS of $10.11 - Thomson Reuters I/B/E/S.  Full Article

AbbVie Inc and Shire Plc agrees to terminate their proposed merger
Tuesday, 21 Oct 2014 02:00am EDT 

Shire Plc:Says AbbVie Inc and Shire Plc have agreed to terminate their proposed merger following decision by AbbVie's Board to withdraw support for proposed transaction.Company's decision was based upon its assessment of the Sept. 22, notice issued by the U.S. Department of Treasury, which re-interpreted longstanding tax principles in uniquely selective manner designed specifically to destroy financial benefits of these types of transactions.The notice introduced an unacceptable level of risk and uncertainty given magnitude of proposed changes and stated intention of the Department of Treasury to continue to revise tax principles to further impact such transactions.  Full Article

Shire Plc's Chief Financial Officer James to step sown
Monday, 20 Oct 2014 02:00am EDT 

Shire Plc:Says that James Bowling, Interim Chief Financial Officer (CFO), has notified the Board of Directors of his decision to step down from his current role to pursue a new career opportunity as CFO of Severn Trent plc.Says James will leave Shire at the end of Q1 2015 and the company will commence a search for a new CFO immediately.  Full Article

Shire Plc announces FDA Acceptance for filing with priority review of supplemental new drug application
Monday, 15 Sep 2014 08:00am EDT 

Shire Plc:Says the US Food and Drug Administration (FDA) has accepted for filing with priority review a supplemental New Drug Application (sNDA) for Vyvanse(lisdexamfetamine dimesylate) Capsules (CII) as a treatment for adults with binge eating disorder (BED).The FDA is expected to provide a decision in Feb. 2015, based on the anticipated Prescription Drug User Fee Act (PDUFA) action date.  Full Article

ANI Pharmaceuticals Inc acquires Vancocin Capsules and additional Vancomycin assets from Shire
Friday, 1 Aug 2014 04:30pm EDT 

ANI Pharmaceuticals Inc:Acquires US rights for Vancocin 125 mg and 250 mg capsules from Shire plc, global biopharmaceutical company.In addition, ANI acquired from Shire approved ANDAs for currently non-marketed products vancomycin hydrochloride injectable 500 mg, 1 gm and 10 gm and vancomycin hydrochloride oral solution 250 mg and 500 mg.ANI paid $11 mln in cash for rights to Vancocin together with existing inventories on hand.Following transition period, ANI intends to launch Vancocin capsules under its own label during the fourth quarter of 2014.Transaction is immediately accretive.  Full Article

Shire Plc enters strategic licensing and collaboration agreement with ArmaGen
Wednesday, 23 Jul 2014 07:00am EDT 

Shire Plc:Announced worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II).This collaboration strengthens Shire's rare disease pipeline of therapies where there is high unmet need, and underscores company's long standing commitment to the Hunter syndrome community.Under terms of agreement, Shire will obtain worldwide commercialization rights for AGT-182 in exchange for payments of about $225 mln to ArmaGen.  Full Article

Shire Plc resolves to pay interim dividend; raises FY 2014 EPS outlook
Friday, 18 Jul 2014 06:06am EDT 

Shire Plc:Board resolved to pay an interim dividend of $0.0383 per ordinary share (2013: $0.03 per ordinary share).Payment date Oct. 03.Register date Sept. 05.Raised FY 2014 non GAAP diluted earnings per ADS guidance to growth in the low-to-mid thirty percent range.Reported EPS of $2.450 in FY 2013.FY 2014 EPS of $3.186 - Thomson Reuters I/B/E/S.  Full Article

AbbVie Inc and Shire Plc reach agreement on terms of recommended combination
Friday, 18 Jul 2014 05:00am EDT 

AbbVie Inc and Shire Plc:Says they have reached agreement on the terms of a recommended combination of Shire with AbbVie.Under the terms of the Merger, Shire shareholders will be entitled to receive: for each Shire Share: 24.44 Pounds in cash and 0.8960 New AbbVie Shares.Immediately following the Transaction, Shire shareholders are expected to hold New AbbVie Shares representing about 25 pct of the issued share capital of New AbbVie, thus offering Shire Shareholders the ability to participate in the future prospects of the Combined Group.AbbVie Stockholders are expected to hold New AbbVie Shares representing about 75 pct of the issued share capital of New AbbVie.AbbVie Board has approved the Transaction and intends to recommend that AbbVie Stockholders vote in favour of the adoption of the US Merger Agreement.In order to undertake the transaction, AbbVie has formed a new company, New AbbVie, which is incorporated in Jersey, Shire's current place of incorporation.Following completion of the transaction, New AbbVie will become the holding company of the Shire Group and the AbbVie Group.  Full Article

Shire Plc updates on AbbVie proposal
Monday, 14 Jul 2014 02:00am EDT 

Shire Plc:Shire requested and has received a further revised proposal from AbbVie on July 13.Revised Proposal comprises 24.44 pounds in cash and 0.8960 shares of new AbbVie per Shire share.Based on the AbbVie share price on 11 July 2014, AbbVie's Revised Proposal has an indicative value of 53.20 pounds per Shire share(1).Under revised proposal, Shire shareholders would own about 25 pct of the combined new AbbVie.Board of Shire has indicated to AbbVie that it would be willing to recommend an offer at the level of the Revised Proposal to Shire shareholders subject to satisfactory resolution of the other terms of offer.Accordingly, Board is in detailed discussions with AbbVie in relation to these terms.Revised Proposal remains subject to the pre-conditions set by AbbVie on July 8 including due diligence and the recommendation of the Board of Shire.There can be no certainty that any firm offer will be made.This statement is being made by Shire with the agreement of AbbVie.  Full Article

AbbVie Inc raises bid for Shire Plc
Tuesday, 8 Jul 2014 07:50am EDT 

AbbVie Inc:Says outline its revised proposal of 22.44 pounds in cash and 0.8568 ordinary shares of New AbbVie for each Shire share.Says fourth proposal represents an indicative value of 51.151 pounds as of July 7.Indicative value of the fourth proposal represents increase of about 11 percent and about a 3 bln pounds increase to indicative offer value of 46.26 Pounds per share.Says increase of 2 pound and about 10 pct in cash per Shire share.Says premium of 75 pct to Shire's closing share price of 29.25 pound on April 17 and about 13 bln pounds of incremental aggregate value for Shire's shareholders.Says premium of 48 pct to Shire's closing share price of 34.67 pounds on May 2 and about 10 bln pounds of incremental aggregate value for Shire's shareholders.Says In addition, this revised indicative proposal increases the ownership that will be held by Shire shareholders to about 24 pct of new holding company of the combined group.  Full Article

Photo

AbbVie says strong results lessen need for big deal

- AbbVie, which this month abandoned its planned $55 billion purchase of Dublin drugmaker Shire , reported impressive quarterly earnings on demand for its Humira arthritis drug and said it could deliver strong long-term growth without rushing into another big merger attempt.

Search Stocks